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Abstract
Gallbladder cancer (GBC) is the most common cancer of the biliary tract and 
has a particularly high incidence in Chile, Japan and northern India. The clinical 
presentation of GBC is often vague or delayed relative to pathologic progression, 
contributing to advanced staging and dismal prognosis at the time of diagnosis. 
In the diagnosis of GBC, differential diagnosis and determination of the local 
extension of tumor are important. For these purposes, imaging modalities such as 
endoscopic ultrasonography (EUS), CT, MRI and magnetic resonance cholangio-
pancreatography (MRCP) are useful. The treatment of localized GBC is based on 
surgery. Chemotherapy has been used extensively in advanced GBC, and we have 
gained some experience with gemcitabine-based combination (with cisplatin and 
oxaliplatin or with capecitabine) regimens.
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1. Introduction
Biliary tract cancers (BTCs) are invasive adenocarcinomas that arise from the 
epithelial lining of the gallbladder and intrahepatic and extrahepatic (hilar and 
distal common bile duct) bile ducts. Gallbladder cancer (GBC) is one of the most 
common malignant tumors of the extrahepatic bile ducts with high incidence in 
Japan, Chile and northern India [1]. The incidence of GBC steadily increases with 
age. Women are affected two to six times more often than men, with predominance 
in whites. Several risk factors are incriminated in the occurrence of this malignant 
tumor, and the main one is gallstone disease. The symptomatology is varied and 
nonspecific, dominated mainly by the pain of the right hypochondrium, which 
poses a problem of early diagnosis and management. The circumstances of discov-
ery are multiple: preoperative, intraoperative and postoperative. GBC is character-
ized by local extension, regional lymph node metastases and distant metastases. 
Usually, GBC is the most aggressive of the biliary cancers with the shortest overall 
survival [1]. Complete surgical resection is the only chance for cure. However, 
only 10% of patients are considered surgical candidates [1]. Among patients who 
undergo curative resection, recurrence rates are high. Patients with unresectable or 
metastatic GBC have a very poor prognosis.
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2. Epidemiology
Gallbladder cancer is the most common cancer of the bile ducts. It accounts for 
3% of all malignant tumors and ranks fifth among digestive cancers after cancer of 
the colon, rectum, stomach and pancreas [2].
The incidence rates are high in Asia and Latin America, relatively high in some 
countries in eastern and central Europe, yet low in the United States and most 
Western and Mediterranean European countries [3]. Gallbladder cancer tends to 
afflict indigenous populations, according to a vast global cancer registry on five 
continents (representing 704.4 million people or 11% of the world population) [4]. 
Mapuche Indians from Valdivia, Chile and South America exhibit the highest rate of 
gallbladder cancer: 12.3/100,000 for males and 27.3/100,000 for females. American 
Indians in New Mexico, USA, follow with an average annual rate of 8.9/100,000. 
For these native people, GBC mortality rates exceed those for breast (8.7/100,000), 
cervical (8.0/100,000), pancreatic (7.4/100,000) and ovarian cancers (7.3/100,000) 
[5]. According to the literature, the sex ratio women-men ranges from 2:1 to 3:1. In 
India and South America, the sex ratio is particularly very high: 5/1 to 6/1. However, 
this difference between the two sexes is less pronounced in East Asia, where the 
sex ratio between men and women [6]. Gallbladder cancer rates tend to increase 
with advancing age. The median age was 67 years in a Memorial Sloan-Kettering 
report of 435 gallbladder cancer patients [7]. Gallbladder cancer is found in 1–2% of 
cholecystectomized patients. It is suggested that the presence of vesicular calculus 
may cause dysplasia of the vesicular mucosa after chronic irritation.
Usually, gallbladder cancer develops over 5–15 years, when metaplasia progresses 
to dysplasia, carcinoma in situ and, then, invasive cancer. Only 10% of patients are 
resectable at the time of surgery [6] with high recurrence rates [8].
3. Diagnosis
3.1 Symptoms and signs of gallbladder carcinoma
The clinical presentation of GBC is often vague or delayed relative to pathologic pro-
gression, contributing to advanced staging and dismal prognosis at the time of diagnosis. 
The clinical presentation is nonspecific. Pain is the most constant symptom. It is present 
in 72–77% of patients [9]. Frequently, it is an intense paroxysmal pain with respiratory 
inhibition, sitting in the right hypochondrium, and with posterior irradiation to the tip 
of the right shoulder blade and anterior to the right shoulder, realizing the classic pain in 
sling. It could be atypical such as epigastralgia and diffuse abdominal pain [9].
Jaundice is observed in 58% of cases. It may be secondary to either tumor inva-
sion or extrinsic compression of the bile ducts by lymphadenopathy or tumor or by 
the presence of liver metastases [10]. Nausea and vomiting are found in 20–49% 
of cases. Clinical examination may be strictly normal at the early stages. The most 
common signs are evidence of a very advanced disease. GBC is manifested in 
15–50% of cases by a mass of the right hypochondrium [11]. Abdominal palpation 
shows a sensitivity of the right hypochondrium in 50–80% of cases [11]. A defense 
of the right hypochondrium or even a positive sign of Murphy can be found on the 
examination, but they remain an unspecific signs [11].
3.2 Diagnosis
Imaging modalities such as ultrasonography (US), endoscopic ultrasonogra-
phy (EUS), computed tomography (CT), magnetic resonance imaging (MRI) and 
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magnetic resonance cholangiopancreatography (MRCP) are useful. EUS has good 
sensitivity in differentiating benign gallbladder diseases from GBC [12]. CT and 
MRI examinations are useful for local and metastatic staging [13].
Ultrasonography is the first examination to be carried out in the diagnostic 
approach in front of a patient presenting a biliary symptomatology or for the preop-
erative study of a vesicular tumor (Figure 1, [14, 15]). It has a sensitivity of 85% and 
a specificity of 80% in the diagnosis of tumors of the gallbladder. Budding image is 
the most common image [15]. It is a vegetative lesion projecting into the vesicular 
lumen. It can be single or multiple and is manifested by a hypo or iso-echoic image 
without shadow cone, irregular edge and implantation base. EUS allows directly 
visualizing the tumor and evaluating its deep extension in the vesicular wall, in the 
hepatic parenchyma and the bile ducts [14]. It also makes it possible to differenti-
ate an early tumor from an advanced tumor. It has a significant sensitivity for the 
etiological diagnosis of neoplastic icterus.
If US suggest a resectable GBC, CT, MRI with magnetic resonance cholangiogra-
phy (MRC) and/or traditional cholangiography often provide additional informa-
tion [16]. These modalities allowed specific staging [17].
CT is to be done in second intension after the ultrasound. It allows the diagnosis 
of GBC in 60–74% of cases. However, its main interest lies in the establishment 
of the tumor extension report. The CT scan aspects are similar to those detected 
by ultrasound. A parietal thickening (Figure 2) or a budding tumor presenting 
as a hypodense, heterogeneous lesion containing hypodense zones and other 
hyperdense secondary to tumor necrosis may be found. The enhancement by the 
tumor may be diffuse or partial, preferentially, peripheral in case of avascular 
central necrosis [18, 19]. Although CT is inferior to ultrasound in depicting mucosal 
irregularity, mural thickening and cholelithiasis, it is superior for evaluating the 
thickness of portions of the gallbladder wall that are obscured by gallstones or 
mural calcification on ultrasound. In unclear cases, hybrid PET-CT systems may 
provide structural and functional information simultaneously and may offer early 
and accurate staging with high specificity [20].
The GBC appears hypo- or isosignal in T1 and hypersignal in T2 at MRI, the 
perilesional inflammation in hypersignal T2 and the calculations are hyposignal. 
Intravenous gadolinium injection increases sensitivity and provides additional data 
Figure 1. 
Ultrasonography shows hyperechoic shadowing portions of gallbladder wall (arrowheads) consistent with 
porcelain gallbladder and hypoechoic, polypoid mass (arrow) suggestive of malignant degeneration into 
gallbladder carcinoma.
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Extension M0 M1
N0 N1* N2**
Tis Carcinoma in situ 0 — — —
T1a Tumor invades the lamina propria I IIIB IVB
T1b Tumor invades the muscular layer
T2 Tumor invades the perimuscular connective tissue; no 
extension beyond the serosa or into the liver
II
T3 Tumor perforates the serosa and/or invades the liver and/
or other adjacent organ or extrahepatic bile ducts
IIIA
T4 Tumor invades the main portal vein or the hepatic artery 
or two or more extrahepatic organs
IVA
*Along the cystic duct, the common hepatic duct, the common hepatic artery and the portal vein.
**Peri-aortic, peri-cellar, celiac trunk and superior mesenteric artery.
Table 1. 
TNM classification (7th edition).
Figure 2. 
Contrast-enhanced CT scan during portal venous phase shows focal nodular thickening (arrow) and diffuse 
gallbladder wall thickening.
Figure 3. 
Axial fat-saturated T2 fast spin image shows a mildly hyperintense, polypoidal and intraluminal gallbladder 
mass (arrow).
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on vascular involvement (Figure 3). The section thickness should be 5 mm or less, 
with a 1–2 mm gap between sections.
Cholangio-MRI is a very useful test for jaundice. It allows to specify the tumor 
extension. It may be the only examination to be performed after ultrasound in 
patients with jaundice. Dynamic MRI with MRCP is an accurate and a reliable 
method of showing GBC and in assessing its local and regional extent as part of 
preoperative assessment [13]. However, only the pathological study could confirm 
the diagnosis of gallbladder carcinoma.
In unclear cases, fluorodeoxyglucose-positron emission tomography (FDG-PET) 
can be considered to establish the benign or the malignant nature of the lesion and 
to obtain a primary staging study (Figure 4).
Table 1 showed TNM classification (7th edition)—UICC—AJCC (2010) cancers 
of gall bladder.
4. Treatment
4.1 Localized GCC
4.1.1 Surgery
4.1.1.1 Tis, T1a, T1b and T2 cancers discovered incidentally on the cholecystectomy
The reference is IVb-V bisegmentectomy with lymph node dissection and 
possibly resection of the bile duct. Bisegmentectomy can be discussed in favor of 
resection of the vesicular bed for these “small cancers,” especially if the cancer 
is located on the free side of the gallbladder. Similarly, resection of the bile duct 
is recommended only in cases of cystic involvement or patent nodal invasion 
(Figure 5) [21].
Systematic secondary resection of trocar orifices is currently controversial.
Figure 4. 
PET/CT image: gallbladder carcinoma (arrow) with lymph nodes (asterisk).
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4.1.1.2 Locally advanced tumors >T2
The extent of liver resection remains controversial. Thus, an IVb-V bisegmen-
tectomy or a more extensive hepatic resection of the trisegmentectomy type may be 
proposed, and for tumors invading the hepatic pedicle, an enlarged right hepatec-
tomy or a central hepatectomy (IV, V, VIII) associated with a segment I resection. 
Segment I resection is especially useful for tumors invading the hepatic hilum. 
Direct invasion of the colon, duodenum or liver is not an absolute contraindication 
to resection, but the morbidity and mortality of these combined resections are high. 
Ganglion dissection should include extensive resection of the hepatic pedicle gan-
glia, anterior and posterior pancreatic ganglia and peeling of the hepatic artery until 
birth in the celiac trunk. Some authors recommend extensive curling, extended to 
the celiac trunk, to the trunk of the superior mesenteric artery down the anterior 
aspect of the aorta (para-aortic ganglia). Involvement of the hepatic pedicle and the 
main bile duct is early in gallbladder cancer without necessarily having a clinical 
impact (jaundice) or contact with the tumor [22]. In addition, removal of the main 
bile duct facilitates nodal dissection of the hepatic pedicle. It is therefore recom-
mended for tumors >T2.
4.1.1.3 Palliative surgery
Surgical biliary shunts (and trans-tumor intubations) have not been demon-
strated superior to prosthetic drainage in terms of quality of life or survival time. 
Their mortality (>25% in several series) and their morbidity are not negligible. 
However, the surgical biliary drainage usually allows prolonged palliation to the 
entire survival patients [22].
4.1.2 Adjuvant treatment
The role of adjuvant chemoradiotherapy is not well defined because of a lack 
of randomized trials. Most of the published studies are retrospective with small 
numbers of patients and a mix of gallbladder and bile duct tumors.
Figure 5. 
Photos d’une bi-segmentectomy IVb-V.
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A systematic review and meta-analysis of published data from 20 studies 
between 1960 and 2010 (6712 patients) showed a nonsignificant improvement 
in overall survival with any adjuvant therapy (chemotherapy (CT), radiotherapy 
(RT) or radiochemotherapy (RCT)) compared to curative surgery alone (HR 0.74, 
p = 0.06). There was no difference between gall bladder tumors and bile duct 
tumors (p = 0.68). The association became significant when both cancer registries 
were excluded, with a significantly higher benefit of CT or RCT than RT alone 
(OR: 0.39, 0.61 and 0.98, respectively, p = 0.02). The greatest benefit of adjuvant 
treatments was observed with N+ status (OR: 0.49, p = 0.004) or R1 (OR: 0.36, 
p = 0.002) [23]. There is no randomized trial of adjuvant RT or RCT. However, 
there are only heterogeneous retrospective series, addressing the issue of adjuvant 
radiation therapy. In these small series, differences in patient selection criteria, 
staging systems, extent of resections, radiation therapy techniques and doses and 
chemotherapy schedules, it is difficult to pinpoint the exact role of adjuvant therapy 
in GBC [24, 25]. Bilcap study is a phase III study that included patients with com-
pletely resected cholangiocarcinoma (CCA) or gallbladder cancer (including liver 
and pancreatic resection, as appropriate), with adequate biliary drainage, no ongo-
ing infection, adequate renal, hematological and liver function and ECOG PS ≤ 2. 
It demonstrated that capecitabine improved overall survival when used as adjuvant 
and should become standard of care [26].
4.2 Metastatic GCC
A small Scandinavian randomized controlled trial showed that a chemother-
apy by 5Fluorouracil and (more etoposide so good general condition) increased 
the quality of life and survival compared exclusive supportive care in patients 
with advanced pancreatic or biliary cancer (6.0 vs. 2.5 months, p < 0.01), how-
ever not significantly in the patient subgroup with biliary cancer, and at the cost 
of considerable toxicity (grade 3–4, 41%) [27]. A single-center Indian random-
ized controlled trial in 81 patients with carcinoma of the gallbladder has shown 
a global survival benefit of chemotherapy by gemcitabine and oxaliplatin not 
only compared to exclusive supportive care but also compared to a chemotherapy 
with 5FU and folinic acid (9.5, 4.5 and 4.6 months respectively, p = 0.039) [28]. 
Collectively, these two trials show that first-line chemotherapy is legitimate 
in patients with advanced biliary cancer whose general condition is not too 
impaired (PS 0–2).
The British randomized controlled trial ABC-02 demonstrated, in 410 patients 
with PS ECOG 0–2 (ECOG 0–1: 88%) and controlled biliary obstruction (total 
bilirubinemia <1.5 N), superiority of gemcitabine-cisplatin combination (GEMCIS 
regimen) on gemcitabine alone (survival overall: 11.7 vs. 8.1 months, hazard ratio 
[HR]: 0.64 [95% CI, 0.52–0.80], p < 0.001) [29]. The benefit of survival with the 
GEMCIS regimen was independent not only of tumor stage (locally advanced or 
metastatic) but also of the primary tumor site (intra- or extrahepatic bile ducts, 
hile, gallbladder, vater bulb). These results were supported by those of the random-
ized trial Phase II Japanese BT-22 in 84 patients (ECOG 0-1: 100%) [30]. These 
results make the GEMCIS regimen the first standard of first-line chemotherapy in 
patients with advanced biliary cancer. The GEMOX scheme [31] is an alternative, 
despite the lack of a randomized controlled trial comparing these two regimens. 
The treatment of metastatic forms is to be discussed according to the general condi-
tion (PS, age). In case of PS > 2, it is recommended to do exclusive support care. In 
case of PS between 0 and 2, it is the indication of a palliative CT by gemcitabine-
cisplatin. The GEMOX scheme is an alternative.
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5. Conclusion
GBC represents a major challenge in oncology. The only curative treatment for 
this disease is surgical resection. The roles of radiation and chemoradiation in the 
neoadjuvant and adjuvant settings remain to be defined in prospective studies. 
Bilcap study demonstrated that capecitabine improved overall survival in adjuvant 
situation. The treatment of metastatic forms is to be discussed according to the 
general condition (PS, age). In case of PS > 2, it is recommended to do exclusive 
support care. For patients with PS between 0 and 2, it is the indication of a palliative 
CT by gemcitabine-cisplatin. The GEMOX scheme represents an alternative.
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